HealthMyne has raised $15m in series B funding round to expand its worldwide commercialization efforts of quantitative imaging decision support (QIDS) platform.


Image: HealthMyne secures $15m funding. Photo: Courtesy of Markus Spiske/Unsplash

The series B round was led by Ascension Ventures, with participation from existing institutional backers Venture Investors, 4490 Ventures, and WARF.

HealthMyne is claimed to be the first company to bring various improved clinical decision support (CDS) workflow modules to radiology and the oncology care continuum in one platform.

The company’s algorithms automate the extraction of quantitative imaging metrics at the Point-of-Read, reducing inter- and intra-reader variability and makes evidence-based metrics such as volume, density, mass, doubling-times, heterogeneity and others available at the Point-of-Care.

The volumetric measurements can then be integrated with clinical data from the EMR, PACS, Radiation Therapy and other systems to drive transformed CDS workflow modules (Cancer Screening, Tumor Board Management, Clinical Trials/Therapy Response Assessment, Incidental Findings, Thoracic Specialty, others), quantitative reports and integrated imaging and clinical patient-centric dashboard.

HealthMyne president and CEO Arvind Subramanian said: “The QIDS platform drives collaboration between the Point-of-Read and Point-of-Care by providing the multidisciplinary care team with intuitive, workflow-integrated software that leverages imaging and clinical data to enhance the quality and cost of care.

“The CDS modules in the platform significantly automate and streamline inefficient and cost-intensive clinical processes to allow busy clinicians to focus their energies on optimizing patient management decisions that make a real impact on patients’ lives.”

HealthMyne said the demand in the market for an intergrated platform which can solve multiple high-impact problems in the diagnosis and treatment of patients across the healthcare enterprise is high.

The company is presently working on a breakthrough in oncology, but the roadmap includes expansion into other major clinical specialties over time.

The QIDS platform offers actionable, patient-centric reports and an integrated clinical and imaging dashboard to optimize collaboration among the multidisciplinary care team.

The platform’s discoverable database also supports data mining and AI-based application development for precision medicine/big data initiatives and for innovative clinical, translational, and commercial research by both medical centers and pharmaceutical/biotech firms.